2
Indication details
- Control Arm
- Single arm cohort study
- FDA Therapeutic Indication
- Treatment of MSI-H or dMMR tumours in adults with unresectable or metastatic gastric cancer, who have disease progression on or following at least one prior therapy
- Tumour Type
-
Gastrointestinal Cancers
- Tumour Sub-type
- Gastric Cancer
- Tumour Stage
- Unresectable or metastatic
- Tumour Sub-Group
- dMMR or MSI-H
- Trial Name
- KEYNOTE-158
- NCT Number
- NCT02628067
- Trial Phase
- Phase II
Approval details
- FDA Approval
- Not FDA approved specifically in gastric cancer (May 2017)
- EMA Approval
- EMA (CHMP) March 2022 EC decision May 2022
Primary Outcome(s)
- Primary Outcome(s)
- ORR
- Evaluated Outcome
- ORR
- Form(s)
- Form 3
Outcome Data
- PFS Control
- 3.2 months
- ORR
- 31.0%
- DoR
- >6 months
Adjustments
- QoL Comment
-
QoL was an exploratory endpoint
Score (after adjustments)
- Preliminary non-curative score
-
2
- Non-curative score
-
2
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 333
- Scorecard version
- 1
- Issue date
- 28.04.2022
- Last update
- 28.11.2023
Legend
Information about symbols, abbrevations and color codes
Red = negative
Green = positive
Grey = neutral
?
Grey + ? = neutral with pending data
- DFS
- Disease-Free Survival
- DoR
- Duration of Response
- EFS
- Event-Free Survival
- HR
- Hazard Ratio
- NEB
- No evaluable benefit
- NI
- Non-inferiority Study
- ORR
- Overall Response Rate
- OS
- Overall Surival
- pCR
- Pathological Complete Response/Remission
- PFS
- Progression-Free Survival
- QoL
- Quality of Life
- RFS
- Relapse-Free Survival
- RR
- Response Rate
QoL adjustments
Other adjustments*
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
QoL adjustments
Red = negative / deterioration
Green = positive / improvement
Other adjustments*
Red = negative / deterioration
Green = positive / improvement
Serious and disabling adverse effects
Red = negative / deterioration
Green = positive / improvement
* Other adjustments include:
- Long-term plateau in the survival curve
- Long-term plateau in the PFS curve
- Early stopping or crossover
- Only improved PFS mature data shows no OS advantage and no improved Qol.